UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Are made-in-Korea Botox products smuggled into China?
The Chinese government has never approved Korean “Botulinum toxin” products...
by Nam Doo-hyun
|
2017-07-10 16:25
라인
Breast cancer therapy Ibrance likely to get insurance benefit
Pfizer’s breast cancer therapy Palbociclib, better known as Ibrance, is lik...
by Nam Doo-hyun
|
2017-07-07 14:26
라인
Is it necessary to write ‘MD’ in license for herb doctors?
To help oriental medicine doctors advance to the United States, it is neces...
by Nam Doo-hyun
|
2017-07-06 17:23
라인
Smaller firms lead domestic stem cell market
Big businesses and small- to medium-sized enterprises (SMEs) account for 17...
by Nam Doo-hyun
|
2017-07-05 13:49
라인
Pompous start, poor showing: R&D report card of oriental medicine
The Traditional Korean Medicine R&D Project, which began with the goal of d...
by Nam Doo-hyun
|
2017-07-05 12:00
라인
A letter to Pfizer CEO Michael Goettler
Dear CEO Michael Goettler,“There was no mention of Ibrance in the question ...
by Nam Doo-hyun
|
2017-07-04 18:57
라인
KISTI present ways to sharpen competitiveness of precision medicine
For precision medicine to take root in Korea, the nation needs to make a mo...
by Nam Doo-hyun
|
2017-06-23 13:35
라인
Why Roche Korea can’t unveil research results of new lung cancer therapy?
Roche Korea is treading carefully in promoting Alecensa (compound: alectini...
by Nam Doo-hyun
|
2017-06-22 16:36
라인
‘Korea needs to develop biomarkers for personalized medical services’
As the biomarker technology remains at a nascent stage in Korea, the indust...
by Nam Doo-hyun
|
2017-06-22 13:24
라인
Sanofi fuels competition in 4-strain flu vaccine market
Competition in the quadrivalent influenza vaccine market will likely become...
by Nam Doo-hyun
|
2017-06-21 11:36
라인
Kwangdong tops pharmaceuticals’ 1Q sales list of health food
Kwangdong Pharmaceutical has recorded the highest sales of functional healt...
by Nam Doo-hyun
|
2017-06-20 18:47
라인
'Bio ventures are for developing new drugs, not making cosmetics'
Bio ventures promoting cosmetic products while claiming to carry the banner...
by Nam Doo-hyun
|
2017-06-19 14:47
라인
Experts call for separate organ to develop bio drugs
The nation needs to set up an independent organization responsible for deve...
by Nam Doo-hyun
|
2017-06-15 13:12
라인
New government set to streamline healthcare R&D projects
The Moon Jae-in administration, which is busy setting up specific strategie...
by Nam Doo-hyun
|
2017-06-15 11:05
라인
Pharmaceutical industry wants to use medical big data at public organizations
Drugmakers are raising their voices to ease regulations so that they can ma...
by Nam Doo-hyun
|
2017-06-14 15:46
라인
Nation needs to develop new drugs to treat senile eye diseases
“Macular degeneration,” changes occurring in macular which results in the v...
by Nam Doo-hyun
|
2017-06-12 12:28
라인
Regulators deem Pfizer’s price for cancer therapy too high
Insurance coverage negotiations for Pfizer’s expensive breast cancer drug, ...
by Nam Doo-hyun
|
2017-06-09 17:31
라인
‘Break global makers’ monopoly on radiotherapy device market’
The domestic market for radiotherapy equipment, for which Korea entirely re...
by Nam Doo-hyun
|
2017-06-08 17:30
라인
Biogen to enter Korean market with new therapy
Global bio industry giant Biogen is highly likely to enter Korea’s market, ...
by Nam Doo-hyun
|
2017-06-07 17:40
라인
Approvals soar for telemedicine SW, equipment
The number of approvals for “U-healthcare gateway” needed for conducting te...
by Nam Doo-hyun
|
2017-06-05 17:18
-
이전
11
12
13
14
15
16
17
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top